Ascentage Pharma Group International American Depository Shares news

The company is strengthening its leadership team with experienced executives to support global expansion and commercialization of its cancer therapy pipeline. Multiple Phase III registrational studies are advancing, and the appointments demonstrate strategic positioning for growth in hematologic malignancies and international markets.

The company's CEO received industry recognition for leadership in drug discovery and innovation. The company has successfully commercialized two innovative therapies and is advancing multiple global Phase III clinical trials cleared by FDA and EMA, demonstrating strong pipeline progress and commercial success.

The company presented multiple positive clinical trial results demonstrating efficacy and manageable safety profiles for both olverembatinib and lisaftoclax across various hematologic malignancies. Key highlights include high response rates (76.2% CCyR, 47.6% MMR for olverembatinib in CML; 62.5% ORR for lisaftoclax in CLL/SLL), successful combination therapy data, and evidence supporting potential standard-of-care positioning. The data supports advancement toward regulatory approvals and commercial potential.

The company presented encouraging clinical data showing strong efficacy metrics (91.3% CCyR, 60.9% MMR) with a stable and manageable safety profile for olverembatinib. The drug is already approved in China and advancing through global Phase III trials, demonstrating progress in pipeline development and commercial expansion.

The company presented encouraging clinical data for alrizomadlin showing preliminary antitumor activity with manageable safety profiles in pediatric solid tumors. The drug achieved a 23.5% objective response rate in combination therapy and received inclusion in China's SPARK Plan, indicating regulatory support and advancement in development pipeline.

The company announced encouraging Phase Ib clinical trial results with high response rates (91% CR/CRi), strong MRD clearance (80%), and manageable safety profile. The combination therapy represents a novel chemotherapy-free treatment option for difficult-to-treat hematologic malignancies, addressing significant unmet medical needs. Multiple FDA/EMA-cleared Phase III trials are ongoing, and the company has strategic partnerships with major pharma companies like Takeda.

The company is presenting significant clinical advances for two approved products at a major international hematology conference. Multiple ongoing registrational Phase III trials and approvals in China demonstrate clinical progress and commercial momentum. The breadth of presentations (17 advances including 8 posters) indicates robust pipeline development and positive clinical data generation.

The company secured six abstracts for presentation at a prestigious international oncology conference, including three rapid oral presentations which are highly competitive selections. This demonstrates scientific validation of their drug candidates and represents continued progress in their clinical development programs. The company also reported 90% year-over-year increase in product sales in 2025, indicating strong commercial traction.

Strong commercial execution with 90% revenue growth in product sales, successful NRDL coverage expansion for Olverembatinib driving 81% sales increase, successful launch of Lisaftoclax generating US$10.1M in five months, robust pipeline with nine Phase III trials underway, and significant cash position of US$353.2M. However, the company reported a substantial net loss of US$177.7M and increased operating expenses, which tempers the overall positive sentiment.

The announcement is a routine earnings report notification with no material business developments, clinical trial results, or financial performance indicators disclosed. The company is simply announcing the timing and format of its financial results presentation, which is standard corporate communication.